Vitellius Géraldine, Poitou Christine, Clément Karine, Petit Jean Michel, Gatta Cherifi Blandine, Amanzougarene Souhila, Derhourhi Mehdi, Saveanu Alexandru, Froguel Philippe, Bonnefond Amélie, Delemer Brigitte, Le Collen Lauriane
Service Diabétologie Endocrinologie Nutrition, CHU Robert Debré, Rue du General Koenig, Reims 51100, France.
Faculty of Sport Sciences, Performance, Health, Metrology, Society Laboratory, University of Reims, Reims 51100, France.
Eur J Endocrinol. 2025 Jun 30;193(1):31-38. doi: 10.1093/ejendo/lvaf127.
Biallelic variants in the pro-opiomelanocortin gene (POMC) can cause hypocortisolism, hypopigmentation, and early-onset obesity. Following the identification of 2 patients of combined pituitary hormone deficiency (CPHD), we investigated the prevalence of this association among carriers of rare pathogenic or likely pathogenic (P/LP) POMC variants.
This study is a case report and systematic literature review.
Genetic analysis was conducted in a family with 2 cousins with childhood-onset obesity and CPHD. We assessed CPHD in carriers for biallelic pathogenic POMC variants using data from the literature and Human Gene Mutation Database. Clinical and biological data were collected, including pituitary axis involvement, obesity onset age, and pituitary imaging results.
The 2 cousins, compound heterozygous for POMC variants, developed CPHD following initial hypocortisolism, with subsequent hypothyroidism, growth hormone deficiency, and hypogonadism. Among 41 patients with biallelic POMC variants identified in the literature, 20 had rare homozygous/compound heterozygous P/LP POMC variants and detailed endocrine evaluations. Of these, 40% presented with CPHD, always associated with early-onset severe obesity and hypocortisolism. Growth hormone deficiency was the most frequent (75%), followed by thyrotropic and gonadotropic deficiencies (62.5%). No anomalies were revealed in pituitary imaging. Two patients recovered the gonadotropic axis after treatment with the MC4R agonist.
These findings underscore the potential for CPHD to occur in carriers of biallelic pathogenic POMC variants. Sequencing the full POMC, including coding and regulatory regions, is crucial in CPHD cases, alongside evaluating all pituitary axes in neonatal hypocortisolism. Beyond weight regulation, setmelanotide may modulate hypothalamic-pituitary function, with implications for fertility.
促肾上腺皮质激素原基因(POMC)的双等位基因变异可导致皮质醇减少、色素沉着减退和早发性肥胖。在确诊2例联合垂体激素缺乏症(CPHD)患者后,我们调查了罕见致病性或可能致病性(P/LP)POMC变异携带者中这种关联的发生率。
本研究为病例报告及系统文献综述。
对一个有2名患儿童期肥胖和CPHD的堂兄弟的家族进行基因分析。我们利用文献数据和人类基因突变数据库评估双等位基因致病性POMC变异携带者的CPHD情况。收集临床和生物学数据,包括垂体轴受累情况、肥胖发病年龄和垂体影像学结果。
这2名堂兄弟为POMC变异的复合杂合子,在最初出现皮质醇减少后发生CPHD,随后出现甲状腺功能减退、生长激素缺乏和性腺功能减退。在文献中鉴定出的41例双等位基因POMC变异患者中,20例有罕见的纯合子/复合杂合子P/LP POMC变异并进行了详细的内分泌评估。其中,40%患有CPHD,均伴有早发性严重肥胖和皮质醇减少。生长激素缺乏最为常见(75%),其次是促甲状腺素和促性腺激素缺乏(62.5%)。垂体影像学未发现异常。2例患者在使用MC4R激动剂治疗后恢复了促性腺轴功能。
这些发现强调了双等位基因致病性POMC变异携带者发生CPHD的可能性。对CPHD病例而言,对整个POMC(包括编码区和调控区)进行测序至关重要,同时要评估新生儿皮质醇减少时所有垂体轴的情况。除了体重调节外,setmelanotide可能会调节下丘脑 - 垂体功能,对生育能力有影响。